Cohance Lifesciences Reports Q2FY26 Results: Strategic Investments Amidst Near-Term Challenges
Cohance Lifesciences reported Q2FY26 results with revenue and PAT declines due to destocking and plant shutdown. The company highlighted strategic investments, capability expansion, and a positive long-term growth outlook.
The announcement has a medium impact due to the reported decline in quarterly financial performance and operational challenges. However, the comprehensive strategic roadmap, significant investments in future growth areas, and positive long-term guidance mitigate a higher negative impact, making it important for understanding future direction.
The company reported a decline in Q2FY26 revenue and PAT, primarily due to pharma destocking, delayed reloads, and a plant shutdown. However, strategic investments in new modalities, capability expansion, and a positive long-term outlook for a US$1 billion vision by 2030 provide a balanced view, preventing a negative sentiment.
* Cohance Lifesciences Limited presented its investor presentation for the unaudited financial results for the quarter and half year ended September 30, 2025 (Q2FY26 and 1HFY26). * Global CDMO demand remains positive, with strong business development traction from CPHI Frankfurt 2025, driven by supply chain de-risking and focus on niche modalities. * FY26 is a year of operational consolidation and capability enhancement, advancing Cohance toward a scalable, customer-centric, and science-led CDMO model. The company is executing an organization upgrade program focused on five capability pillars to support its 2030 US$1 billion (₹85 billion) vision. * Challenges in FY26 include pharma destocking in key molecules, delayed reloads of Phase 2-3 molecules, a Nacharam plant shutdown (production now resumed in a phased manner), and a slowdown in biotech funding which pushed NJ Bio project shipments by 2-3 quarters. * Mid- to long-term growth drivers include customer base expansion, pipeline breadth (high-potent, ADC, oligo programs), RFQ funnel quality, new product validation/filings, and capability investments like OEB-6 block and GMP oligo lab scale-up. * For 1HFY26, CDMO reported a decline of 4% YoY due to de-stocking and biotech funding impact. API+ declined 4% YoY primarily due to the Nacharam plant shutdown. Specialty Chemicals (Agro + Performance Chem) reported a growth of 84% YoY. * Q2FY26 Financial Highlights: * Platform revenue growth was 14% YoY, adjusting for de-stocking. * Pharma CDMO declined by 8% YoY, while API+ declined by 22% YoY. * Specialty Chemicals posted 166% YoY growth. * Gross margins expanded to 74.6% in Q2FY26 and 73.8% in 1HFY26. * Adjusted EBITDA margin stood at 23.2% in Q2FY26 and 23.8% in 1HFY26. * Revenue from Operations for Q2FY26 was ₹5.56 billion, an 8.0% decline YoY. For 1HFY26, it was ₹11.049 billion, a 1.2% increase YoY. * Adjusted Profit After Tax (PAT) for Q2FY26 was ₹0.71 billion, a 50.8% decline YoY. For 1HFY26, it was ₹1.302 billion, a 42.3% decline YoY. * The company generated free cash flow of ₹1.7 billion in 1HFY26, with cash on books at ₹3.91 billion and deployed capex of ₹1.05 billion. * Revised Outlook for FY26: The company expects flattish revenue growth YoY, with 2H performance anticipated to be better than 1H due to deferred shipments, new commercial project wins, and audit clearances. * Mid-longer-term outlook: Growth is expected to return in FY27, driven by new wins, existing business, and re-stocking/re-loads on the CDMO side. The company maintains its mid-longer-term guidance of US$1 billion (₹85 billion) with mid-30s EBITDA margins by 2030.
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.